Cargando…
The impact of early therapies for COVID-19 on death, hospitalization and persisting symptoms: a retrospective study
PURPOSE: Oral antivirals (nirmatrelvir/ritonavir and molnupiravir), intravenous short treatment of remdesivir and anti-SARS-CoV-2 monoclonal antibodies (mAbs) have been used for early COVID-19 treatments in high risk of disease progression patients. The term long COVID has been used to refer to a ra...
Autores principales: | Bertuccio, Paola, Degli Antoni, Melania, Minisci, Davide, Amadasi, Silvia, Castelli, Francesco, Odone, Anna, Quiros-Roldan, Eugenia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079146/ https://www.ncbi.nlm.nih.gov/pubmed/37024626 http://dx.doi.org/10.1007/s15010-023-02028-5 |
Ejemplares similares
-
Monoclonal Antibodies against SARS-CoV-2: Current Scenario and Future Perspectives
por: Quiros-Roldan, Eugenia, et al.
Publicado: (2021) -
Characteristics of the population with mild COVID-19 symptoms eligible for early treatment attended in a single center in Northern Italy
por: Magro, Paola, et al.
Publicado: (2023) -
Non-neutralizing antibodies: Deleterious or propitious during SARS-CoV-2 infection?
por: Zanella, Isabella, et al.
Publicado: (2022) -
An HIV elite controller patient carrying the homozygous H63D variant in the homeostatic iron regulator gene: A case report
por: Zanella, Isabella, et al.
Publicado: (2021) -
Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review
por: Tiecco, Giorgio, et al.
Publicado: (2022)